

Please enter the following amendments.

1-70. (canceled)

71. (previously presented) A solution having a pH of from 5 to 10, comprising from 200 mM arginine to 300 mM arginine, and further comprising more than 0.2 mg/ml of a polypeptide selected from the group consisting of (i) human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4, (ii) human TFPI having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine, and (iii) muteins of (i) or (ii) having from 1 to 5 amino acid substitutions.

72. (previously presented) The solution of claim 71 wherein said arginine is L-arginine.

73. (previously presented) The solution of claim 71 comprising from more than 0.2 to 20 mg/ml of said polypeptide.

74. (previously presented) The solution of claim 72 wherein the polypeptide is human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine.

75. (previously presented) The solution of claim 71 comprising 300 mM arginine.

76. (previously presented) The solution of claim 74 having a citrate/citric acid buffer at a total buffer concentration from 5 mM to 300 mM.

77. (previously presented) The solution of claim 71 having a pH of 5.5 and comprising human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine, 300 mM L-arginine, and a citrate/citric acid buffer at a total buffer concentration of 20 mM.

78. (previously presented) A solution having a pH of from 5 to 10, comprising more than 0.2 mg/ml of a polypeptide selected from the group consisting of (i) human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4, (ii) human TFPI having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine, and (iii) muteins of (i) or (ii) having from 1 to 5 amino acid substitutions, and further comprising a solubilizer selected from the group consisting of sucrose, mannitol, sorbitol, citrate, isocitrate, succinate, malate, polyphosphate, acetate, polysorbate-80, polyethylene glycol, histidine, imidazole, glutamate, glycine, ammonium sulfate, and sodium dodecyl sulfate.

79. (previously presented) The solution of claim 78 wherein the polypeptide is present at a concentration from 1 to 20 mg/ml.

80. (previously presented) The solution of claim 79 wherein the polypeptide is present at a concentration from 1 to 10 mg/ml.

81. (canceled)

82. (canceled)

83. (previously presented) The solution of claim 78 wherein the solution comprises 0.5M sodium citrate.

84. (previously presented) The solution of claim 78 wherein the solution comprises 0.5M sodium isocitrate.

85. (previously presented) The solution of claim 78 wherein the pH of the solution is below pH 7.0, and wherein the solubilizer is not glycine.

86. (previously presented) The solution of claim 78 wherein the solubilizer is acetate ion and the acetate ion is present in the solution at a concentration from 5 mM to 200 mM.

87. (previously presented) The solution of claim 78 wherein the solubilizer is citrate ion and the citrate ion is present in the solution as sodium citrate or potassium citrate at a concentration from 50 mM to 500 mM.

88. (previously presented) The solution of claim 78 wherein the solubilizer is isocitrate ion and the isocitrate ion is present in the solution as sodium isocitrate or potassium isocitrate at a concentration from 100 mM to 500 mM.

89. (previously presented) The solution of claim 78 wherein the solubilizer is glycine and the glycine is present in the solution at a concentration from 5 mM to 20 mM.

90. (previously presented) The solution of claim 78 wherein the solubilizer is glutamate and the glutamate is present in the solution at a concentration from 5 mM to 20 mM.

91. (previously presented) The solution of claim 78 wherein the solubilizer is succinate ion and the succinate ion is present in the solution as sodium succinate at a concentration from 5 mM to 20 mM.

92. (previously presented) The solution of claim 78 wherein the solubilizer is histidine and the histidine is present in the solution at a concentration from 5 mM to 20 mM.

93. (previously presented) The solution of claim 78 wherein the solubilizer is imidazole and the imidazole is present in the solution at a concentration from 5 mM to 20 mM.

94. (previously presented) The solution of claim 78 wherein the solubilizer is sodium dodecyl sulfate and the sodium dodecyl sulfate is present in the solution at a concentration from 0.001 % to 0.1 % (weight / volume).

95. (previously presented) The solution of claim 78 wherein the solubilizer is polyethylene glycol and the polyethylene glycol is present in the solution at a concentration from 0.2 % to 10 % (weight / volume).

96. (previously presented) The solution of claim 78 wherein the solubilizer is sucrose and the sucrose is present in the solution at a concentration from 0.2 % to 10 % (weight / volume).

97. (previously presented) The solution of claim 78 wherein the solubilizer is mannitol and the mannitol is present in the solution at a concentration from 1.0 % to 5.0 % (weight / volume).

98. (previously presented) The solution of claim 78 wherein the solubilizer is sorbitol and the sorbitol is present in the solution at a concentration from 0.2 % to 10 % (weight / volume).

99. (previously presented) The solution of claim 78 comprising at least 20 mM citrate.

100. (previously presented) The solution of claim 78 comprising at least 5 mM sodium acetate.

101. (previously presented) The solution of claim 78 comprising at least 0.005% (w/v) polysorbate-80.

102. (previously presented) The solution of claim 78 comprising at least 5 mM histidine.

103. (previously presented) The solution of claim 78 comprising at least 10 mM imidazole.

104. (previously presented) The solution of claim 78 comprising at least 1% (w/v) glutamate.

105. (previously presented) The solution of claim 78 comprising at least 0.1% (w/v) polyphosphate.

106. (previously presented) The solution of claim 78 comprising at least 120 mM ammonium sulfate.

107. (previously presented) The solution of claim 78 comprising at least 0.02% (w/v) sodium dodecyl sulfate.

108. (previously presented) A solution according to any one of claims 78-107 wherein the polypeptide is human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine.

109. (previously presented) A solution according to claim 108 which is pharmaceutically acceptable.

110. (previously presented) A solution according to any one of claims 78-107 which is pharmaceutically acceptable.

111. (previously presented) An aqueous composition comprising (1) a polypeptide selected from the group consisting of (i) human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4, (ii) human TFPI having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine, and (iii) muteins of (i) or (ii) having from 1 to 5 amino acid substitutions, and (2) a stabilizer of the polypeptide selected from the group consisting of polysorbate-80, mannitol, sucrose, chloride, acetate, citrate, phosphate, and mixtures thereof, wherein the half-life at 40°C of the polypeptide in said composition, as determined using prothrombin time, is greater than that of a composition comprising TFPI, 150 mM sodium chloride, and 10 mM sodium phosphate and having a pH of 6.

112. (previously presented) The composition of claim 111 wherein the half life is from 20 to about 70 days.

113. (previously presented) The composition of claim 112 wherein the pH of the composition is from 5 to 10.

114. (previously presented) The composition of claim 113 wherein the stabilizer is selected from the group consisting of sodium chloride at a concentration of at least 150 mM, sucrose at a concentration of at least 8% (weight/volume), and mannitol at a concentration of at least 4.5% (weight/volume).

115. (previously presented) The composition of claim 114 wherein the stabilizer is sodium chloride at a concentration of at least 150 mM.

116. (previously presented) The composition of claim 115 further comprising 10 mM sodium citrate.

117. (previously presented) The composition of claim 116 having a pH of about 5.5.

118. (previously presented) The composition of claim 115 having a sodium chloride concentration of at least 500 mM sodium chloride.

119. (previously presented) The composition of claim 118 further comprising a sodium phosphate buffer at a total buffer concentration of about 10 mM.

120. (previously presented) The composition of claim 119 having a pH of about 6.0.

121. (previously presented) The composition of claim 114 wherein the stabilizer is sucrose at a concentration of at least 8% (weight/volume).

122. (previously presented) The composition of claim 121 further comprising 10 mM sodium acetate.

123. (previously presented) The composition of claim 122 having a pH of about 5.5.

124. (previously presented) The composition of claim 114 wherein the stabilizer is mannitol at a concentration of at least 4.5% (weight/volume).

125. (previously presented) The composition of claim 124 further comprising 10 mM sodium acetate.

126. (previously presented) The composition of claim 125 having a pH of about 5.5.

127. (previously presented) The composition of claim 111 comprising 150 mM sodium chloride, 0.005% (weight/volume) polysorbate-80, and sodium phosphate buffer at a concentration of at least 50 mM and having a pH of 7.

128. (previously presented) A composition of any of claims 111-127 wherein the polypeptide is human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine.

129-262. (canceled)

263. (previously presented) The solution of claim 71 comprising more than 1 mg/ml of said polypeptide.

264. (previously presented) The solution of claim 263 comprising more than 5 mg/ml of said polypeptide.

265. (previously presented) The solution of claim 264 comprising more than 10 mg/ml of said polypeptide.

266. (previously presented) The solution of claim 265 comprising more than 20 mg/ml of said polypeptide.

267. (previously presented) The solution of claim 73 comprising from more than 0.2 to 20 mg/ml of said polypeptide.

268. (previously presented) The solution of claim 267 comprising from 1 to 10 mg/ml of said polypeptide.

269. (previously presented) The solution of claim 267 comprising from 5 to 20 mg/ml of said polypeptide.

270. (previously presented) A solution having a pH of from 5 to 10, comprising more than 0.2 mg/ml of a polypeptide selected from the group consisting of (i) human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4, (ii) human TFPI having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine, and (iii) muteins of (i) or (ii) having from 1 to 5 amino acid substitutions, and further comprising a solubilizer selected from the group consisting of

phosphate at a concentration of less than 20 mM or at least 500 mM; acetate at a concentration of at most 20 mM or at least 100 mM; and sulfate at a concentration of at least 120 mM.

271. (previously presented) The solution of claim 270 wherein the phosphate is sodium phosphate and the sodium phosphate is at a concentration selected from the group consisting of 10 mM and 500 mM.

272. (previously presented) The solution of claim 270 wherein the acetate is sodium acetate and the sodium acetate is at a concentration selected from the group consisting of 5 mM, 10 mM, 20 mM, 100 mM, and 200 mM.

273. (previously presented) The solution of claim 270 wherein the sulfate is sodium sulfate at a concentration of 260 mM.

274. (previously presented) The solution of claim 270 wherein the sulfate is ammonium sulfate and the ammonium sulfate is at a concentration selected from the group consisting of 120 mM, 500 mM, and 1 M.

275. (previously presented) A solution having a pH of from 5 to 10, comprising more than 0.2 mg/ml of a polypeptide selected from the group consisting of (i) human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4, (ii) human TFPI having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine, and (iii) muteins of (i) or (ii) having from 1 to 5 amino acid substitutions, and further comprising a solubilizer selected from the group consisting of acetate and more than 20 mM phosphate, wherein the solution does not comprise urea.

276. (previously presented) A solution having a pH of from 5 to 10, comprising more than 0.2 mg/ml of a polypeptide selected from the group consisting of (i) human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4, (ii) human TFPI having the amino acid sequence shown in Figure 4 and having one further amino acid which is

an amino-terminal alanine, and (iii) muteins of (i) or (ii) having from 1 to 5 amino acid substitutions, and further comprising a first solubilizer selected from the group consisting of phosphate, sulfate, and acetate, and a second solubilizer selected from the group consisting of sodium chloride at a concentration of at least 1.0 M, magnesium chloride, triphosphate, succinic acid, tartaric acid, malic acid, isocitrate, sodium citrate, phosphate glass, mannitol, sucrose, PEG-400, polysorbate-80, and sorbitol.

277. (currently amended) An aqueous composition comprising (1) a polypeptide selected from the group consisting of (i) human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4, (ii) human TFPI having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine, and (iii) muteins of (i) or (ii) having from 1 to 5 amino acid substitutions, and (2) a stabilizer of the polypeptide ~~selected from the group consisting of~~ selected from the group consisting of polysorbate-80, mannitol, sucrose, chloride, acetate, citrate, phosphate, and mixtures thereof, wherein the half-life at 40°C of the polypeptide in said composition, as determined using prothrombin time, is from about 15 days to about 70 days.

278. (previously presented) An aqueous composition according to claim 277, wherein the half-life is from about 20 days to about 70 days.

279. (new) An aqueous composition according to claim 277, comprising at least 0.15 mg/ml of said polypeptide.

280. (new) An aqueous composition according to claim 279, comprising more than 0.2 mg/ml of said polypeptide.

281. (new) An aqueous composition according to claim 277, further comprising from 200 mM arginine to 300 mM arginine.

282. (new) An aqueous composition according to claim 277, having a pH of 5.5 and comprising human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine, 300 mM L-arginine, and a citrate/citric acid buffer at a total buffer concentration of 20 mM.

283. (new) An aqueous composition according to claim 277, having a pH of below 7.0.

284. (new) An aqueous composition according to claim 283, having a pH of about 5.5.

285. (new) An aqueous composition according to claim 277, comprising at least 20 mM citrate.

286. (new) An aqueous composition comprising (1) a polypeptide selected from the group consisting of (i) human Tissue Factor Pathway Inhibitor (TFPI) having the amino acid sequence shown in Figure 4, (ii) human TFPI having the amino acid sequence shown in Figure 4 and having one further amino acid which is an amino-terminal alanine, and (iii) muteins of (i) or (ii) having from 1 to 5 amino acid substitutions, and further comprising from 200 mM arginine to 300 mM arginine.

287. (new) An aqueous composition according to claim 286, comprising at least 0.15 mg/ml of said polypeptide.

288. (new) An aqueous composition according to claim 287, comprising more than 0.2 mg/ml of said polypeptide.

289. (new) An aqueous composition according to claim 286, having a pH of below 7.0.

290. (new) An aqueous composition according to claim 289, having a pH of about 5.5.

291. (new) An aqueous composition according to claim 286, further comprising at least 20 mM citrate.